News
InSphero human liver disease platform selected to test Cyclerion’s sGC stimulator technology as potential therapeutic approach for NASH and fibrosis. Read more >>
InSphero launches industry's first automation-compatible 3D human liver disease model for NAFLD and NASH. Read More >>
InSphero achieves new milestone with Akura™ Flow organ-on-a-chip technology. Read more >>
InSphero partners with ALPCO to advance diabetes research. Read more >>
SCIENCE
Why InSphero?
Enabling Technology
3D Select™ Process
Microtissue Formats
Organ-on-a-chip Systems
Live Microtissue Shipping
Publications
Peer-reviewed Papers
White Papers
Posters
Blog
Videos and Webinars
APPLICATIONS
Application Overview
Liver Toxicology
DILI Prediction
Mechanistic Assays
Metabolic Disease
Diabetes & Islet Research
Liver Disease
Oncology
Efficacy Testing
Immuno-oncology
PRODUCTS
3D InSight™ Platforms
Liver
Liver Disease
Steatosis
NASH
Liver Toxicology
Human
Animal
Islet
Human
Rat
Platform Add-Ons
Tumor
Assay-ready Models
PDX Models
Custom Model Development
How to Order
SERVICES
Services Overview
In Vitro
Toxicology
14 Day Hepatotoxicity
Custom Mechanistic and Investigative Studies
Mitochondrial Toxicity
Pancreatic Endocrine Toxicity
Embryotoxicity (DART)
Diabetes and NASH Drug Discovery
Diabetes Drug Testing
NASH Drug Testing
Oncology Drug Discovery
Custom Tumor Model Development
Efficacy Testing
Combinatorial Drug Testing
Tumor Relapse Assay
Antibody Penetration
Immuno-Oncology
How to Get Started
ABOUT
About InSphero
Leadership
Careers
Contact Us
Our Partners
News & Events
Newsletter
Media Releases
Fairs, Conferences & Events
SUPPORT
Help Center
Production Schedule
Protocols and Manuals
Customer Portal
BLOG
InSphero_difference_icon2
